Trodelvy® Demonstrates Positive Efficacy Treating Both Platinum-Ineligible and Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer

(marketscreener.com) – Oral Presentation Highlights Trodelvy Efficacy of 13.5 Months Overall Survival in Patients with Platinum-Ineligible Metastatic UC After Checkpoint Inhibitor Therapy –– Trodelvy Demonstrated 12.8 Months Overall Survival in Patients with Metastatic UC Whose Disease Progressed Rapidly Following Platinum-Based Chemotherapy...https://www.marketscreener.com/quote/stock/GILEAD-SCIENCES-INC-4876/news/Trodelvy-Demonstrates-Positive-Efficacy-Treating-Both-Platinum-Ineligible-and-Rapidly-Progressing-43019775/?utm_medium=RSS&utm_content=20230217